Santen Pharmaceutical (OTCMKTS:SNPHY) Sees Unusually-High Trading Volume - Time to Buy?

Key Points

• Unusually-high trading volume: About 31,899 shares traded on Friday (a 94% increase vs. the prior session) while the stock traded at $10.43 and was reported down roughly 6.1% from the prior close.
• Analyst stance: Zacks Research recently upgraded Santen to a "Hold" (the consensus rating shown is currently "Hold" based on one analyst).
• Company fundamentals: Santen is a Japan-based ophthalmology specialist with a market cap of $3.22 billion and an unusually low reported P/E ratio of 0.10, with 50- and 200-day SMAs near $10.96 and $10.66.

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY - Get Free Report) saw unusually-high trading volume on Friday . Approximately 31,899 shares changed hands during mid-day trading, an increase of 94% from the previous session's volume of 16,471 shares.The stock last traded at $10.43 and had previously closed at $10.6750.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded Santen Pharmaceutical to a "hold" rating in a report on Monday, April 13th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat, Santen Pharmaceutical presently has an average rating of "Hold".

Santen Pharmaceutical Trading Down 6.1%

The business has a fifty day simple moving average of $10.96 and a two-hundred day simple moving average of $10.66. The company has a market cap of $3.22 billion and a PE ratio of 0.10.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.